CellaVision AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0000683484
SEK
152.00
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

37.7 k

Shareholding (Dec 2016)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

High Management Efficiency with a high ROE of 19.18%

 
2

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 15.75

 
3

Positive results in Dec 25

4

With ROE of 18.37%, it has a very expensive valuation with a 5.22 Price to Book Value

5

Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks

 
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 3,578 Million (Small Cap)

stock-summary
P/E

28.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.01%

stock-summary
Debt Equity

-0.18

stock-summary
Return on Equity

17.25%

stock-summary
Price to Book

4.03

Revenue and Profits:
Net Sales:
197 Million
(Quarterly Results - Dec 2025)
Net Profit:
43 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.78%
0%
-0.78%
6 Months
-13.14%
0%
-13.14%
1 Year
-7.32%
0%
-7.32%
2 Years
-34.9%
0%
-34.9%
3 Years
-25.85%
0%
-25.85%
4 Years
-51.5%
0%
-51.5%
5 Years
-50.97%
0%
-50.97%

CellaVision AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
9.99%
EBIT Growth (5y)
12.88%
EBIT to Interest (avg)
15.75
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.19
Sales to Capital Employed (avg)
0.87
Tax Ratio
20.41%
Dividend Payout Ratio
42.85%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
26.30%
ROE (avg)
19.18%

Valuation key factors

Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
5.22
EV to EBIT
21.16
EV to EBITDA
17.85
EV to Capital Employed
5.98
EV to Sales
5.55
PEG Ratio
6.74
Dividend Yield
0.01%
ROCE (Latest)
28.26%
ROE (Latest)
18.37%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2016stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 5.62% vs -6.93% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 4.16% vs -18.85% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "197.20",
          "val2": "186.70",
          "chgp": "5.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "63.50",
          "val2": "58.90",
          "chgp": "7.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "2.70",
          "chgp": "-62.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "42.60",
          "val2": "40.90",
          "chgp": "4.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "279.40%",
          "val2": "275.10%",
          "chgp": "0.43%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 4.95% vs 6.78% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 8.81% vs 7.98% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "759.00",
          "val2": "723.20",
          "chgp": "4.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "234.40",
          "val2": "218.70",
          "chgp": "7.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "10.70",
          "val2": "1.90",
          "chgp": "463.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "153.10",
          "val2": "140.70",
          "chgp": "8.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "266.20%",
          "val2": "245.70%",
          "chgp": "2.05%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
197.20
186.70
5.62%
Operating Profit (PBDIT) excl Other Income
63.50
58.90
7.81%
Interest
1.00
2.70
-62.96%
Exceptional Items
0.00
0.00
Consolidate Net Profit
42.60
40.90
4.16%
Operating Profit Margin (Excl OI)
279.40%
275.10%
0.43%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is 5.62% vs -6.93% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 4.16% vs -18.85% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
759.00
723.20
4.95%
Operating Profit (PBDIT) excl Other Income
234.40
218.70
7.18%
Interest
10.70
1.90
463.16%
Exceptional Items
0.00
0.00
Consolidate Net Profit
153.10
140.70
8.81%
Operating Profit Margin (Excl OI)
266.20%
245.70%
2.05%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 4.95% vs 6.78% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 8.81% vs 7.98% in Dec 2024

stock-summaryCompany CV
About CellaVision AB stock-summary
stock-summary
CellaVision AB
Pharmaceuticals & Biotechnology
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
Company Coordinates stock-summary
Company Details
Mobilvagen 12 , LUND None : 223 62
stock-summary
Tel: 46 46 460160046 46 4601652
stock-summary
Registrar Details